X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-25 | KDNY | Chinook Therapeutics, Inc. | Dobmeier Eric | Pres, CEO | P - Purchase | $13.03 | +5,000 | 205,880 | +2% | +$65,148 | ||||||
2022-05-27 | VTRS | Viatris Inc | Taddese Menassie | See Remarks | S - Sale | $12.07 | -8,813 | 0 | -100% | -$106,406 | ||||||
| D | 2022-05-26 | VIRX | Viracta Therapeutics, Inc. | Royston Ivor | CEO, Pres | S - Sale+OE | $1.90 | -13,162 | 619,529 | -2% | -$25,022 | |||||
| D | 2022-05-26 | VIRX | Viracta Therapeutics, Inc. | Rojkjaer Lisa | Chief Medical Officer | S - Sale+OE | $1.90 | -2,154 | 42,168 | -5% | -$4,095 | |||||
2022-05-26 | DRRX | Durect Corp | Robertson Judith J. | Dir | P - Purchase | $0.39 | +65,000 | 265,000 | +33% | +$25,597 | ||||||
| D | 2022-05-26 | VIRX | Viracta Therapeutics, Inc. | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $1.90 | -3,596 | 79,142 | -4% | -$6,836 | |||||
2022-05-27 | CLNN | Clene Inc. | Matlin David J | Dir | P - Purchase | $2.27 | +35,000 | 2,211,106 | +2% | +$79,450 | ||||||
| D | 2022-05-27 | UTHR | United Therapeutics Corp | Maxwell Linda | Dir | S - Sale+OE | $228.00 | -2,000 | 0 | -100% | -$456,000 | |||||
2022-05-25 | RAPT | Rapt Therapeutics, Inc. | Column Group Ii, LP | 10% | P - Purchase | $12.45 | +1,900 | 3,189,178 | 0% | +$23,664 | ||||||
2022-05-25 | RAPT | Rapt Therapeutics, Inc. | Column Group Ii, LP | 10% | P - Purchase | $12.45 | +1,900 | 3,189,178 | 0% | +$23,664 | ||||||
| AD | 2021-02-09 | ANGN | Angion Biomedica Corp. | Venkatesan Jay | See Remarks | S - Sale+OE | $16.00 | -159,177 | 1,439,525 | -10% | -$2,546,832 | |||||
| AD | 2021-02-09 | ANGN | Angion Biomedica Corp. | Ganzi Victor F | Dir | S - Sale+OE | $16.00 | -246,720 | 823,117 | -23% | -$3,947,520 | |||||
2022-05-25 | ANGN | Angion Biomedica Corp. | Venkatesan Jay | See Remarks | P - Purchase | $1.25 | +11,313 | 1,891,947 | +1% | +$14,103 | ||||||
2022-05-25 | GANX | Gain Therapeutics, Inc. | Richman Eric I | CEO | P - Purchase | $2.58 | +2,482 | 232,558 | +1% | +$6,404 | ||||||
2022-05-25 | IMRX | Immuneering Corp | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | P - Purchase | $3.92 | +2,551 | 332,685 | +1% | +$10,000 | ||||||
| M | 2022-05-25 | TYME | Tyme Technologies, Inc. | Hoffman Steve | Dir, 10% | S - Sale | $0.24 | -156,250 | 20,335,066 | -1% | -$37,500 | |||||
| DM | 2022-05-25 | ENSC | Ensysce Biosciences, Inc. | Kirkpatrick Lynn | CEO | P - Purchase | $0.50 | +97,000 | 381,851 | +34% | +$48,299 | |||||
2022-05-26 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $311.27 | -178,390 | 105,033,810 | 0% | -$55,526,821 | ||||||
| M | 2022-03-18 | JSDA | Jones Soda Co | Sol Global Investments Corp. | 10% | P - Purchase | $0.39 | +274,185 | 33,116,230 | +1% | +$108,299 | |||||
| M | 2022-03-04 | JSDA | Jones Soda Co | Sol Global Investments Corp. | 10% | S - Sale | $0.53 | -1,200,000 | 33,116,230 | -3% | -$638,600 | |||||
2022-05-26 | LIAN | Lianbio | Perceptive Advisors LLC | Dir, 10% | P - Purchase | $3.13 | +69,000 | 56,560,211 | 0% | +$215,970 | ||||||
2022-05-25 | KMPH | Kempharm, Inc | Tierney David S | Dir | P - Purchase | $4.39 | +2,000 | 5,835 | +52% | +$8,780 | ||||||
| M | 2022-05-24 | MRSN | Mersana Therapeutics, Inc. | Hack Andrew A. F. | Dir | P - Purchase | $3.22 | +265,155 | 8,568,154 | +3% | +$854,175 | |||||
2022-05-24 | VRPX | Virpax Pharmaceuticals, Inc. | Sendrow Jerrold | Dir | P - Purchase | $1.29 | +4,500 | 9,006 | +100% | +$5,805 | ||||||
| DM | 2022-05-25 | UTHR | United Therapeutics Corp | Rothblatt Martine A | Chairperson, CEO | S - Sale+OE | $223.93 | -6,000 | 651,845 | -1% | -$1,343,581 | |||||
2022-05-26 | KALA | Kala Pharmaceuticals, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $0.36 | -1,005,686 | 7,039,613 | -13% | -$365,667 | ||||||
2022-05-24 | IGMS | Igm Biosciences, Inc. | Takimoto Chris H | Chief Medical Officer | S - Sale | $17.10 | -938 | 36,864 | -2% | -$16,043 | ||||||
2022-05-26 | IGMS | Igm Biosciences, Inc. | Tahir Misbah | CFO | S - Sale | $17.10 | -950 | 33,698 | -3% | -$16,247 | ||||||
2022-05-24 | IGMS | Igm Biosciences, Inc. | Schwarzer Fred | CEO, Pres | S - Sale | $17.10 | -1,362 | 230,705 | -1% | -$23,294 | ||||||
| D | 2022-05-26 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $223.55 | -5,000 | 750 | -87% | -$1,117,723 | |||||
2022-05-24 | IGMS | Igm Biosciences, Inc. | Keyt Bruce | Chief Scientific Officer | S - Sale | $17.10 | -939 | 40,502 | -2% | -$16,058 | ||||||
2022-05-24 | IGMS | Igm Biosciences, Inc. | Gauthier George | Chief Commercial Officer | S - Sale | $17.10 | -1,340 | 25,236 | -5% | -$22,917 | ||||||
2022-05-24 | IGMS | Igm Biosciences, Inc. | Decker Lisa Lynn | Chief Business Officer | S - Sale | $17.10 | -1,362 | 21,535 | -6% | -$23,293 | ||||||
2022-05-24 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | 10% | P - Purchase | $0.89 | +16,100 | 37,604,651 | 0% | +$14,306 | ||||||
| D | 2022-05-26 | UTHR | United Therapeutics Corp | Sullivan Louis W | Dir | S - Sale+OE | $225.01 | -6,310 | 11,100 | -36% | -$1,419,781 | |||||
| M | 2022-05-24 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $13.42 | +61,120 | 18,103,936 | 0% | +$819,948 | |||||
| M | 2022-05-24 | NGM | Ngm Biopharmaceuticals Inc | Goeddel David V | Dir, 10% | P - Purchase | $13.42 | +61,120 | 18,234,936 | 0% | +$819,948 | |||||
2022-05-25 | PNT | Point Biopharma Global Inc. | Fleshner Neil E. | Chief Medical Officer | S - Sale | $7.51 | -564,204 | 3,256,574 | -15% | -$4,237,172 | ||||||
| M | 2022-05-24 | MACK | Merrimack Pharmaceuticals Inc | Crocker Gary L | See Remarks | P - Purchase | $5.09 | +2,455 | 126,004 | +2% | +$12,495 | |||||
2022-05-25 | EDSA | Edesa Biotech, Inc. | Brooks Michael J | Pres | P - Purchase | $1.74 | +3,500 | 20,241 | +21% | +$6,090 | ||||||
2022-05-25 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $308.95 | -41,610 | 105,212,200 | 0% | -$12,855,267 | ||||||
2022-05-25 | LQDA | Liquidia Corp | Caligan Partners LP | See Remarks, 10% | P - Purchase | $3.40 | +79,400 | 10,393,627 | +1% | +$269,960 | ||||||
2022-05-25 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $2.98 | +50,000 | 229,202,822 | 0% | +$148,866 | ||||||
2022-05-25 | KMPH | Kempharm, Inc | Mickle Travis C | Pres, CEO | P - Purchase | $4.38 | +13,000 | 171,774 | +8% | +$56,996 | ||||||
| D | 2022-05-23 | AMPH | Amphastar Pharmaceuticals, Inc. | Lee Howard | Dir | S - Sale+OE | $34.93 | -10,000 | 138,776 | -7% | -$349,323 | |||||
2022-05-24 | DRRX | Durect Corp | Azab Mohammad | Dir | P - Purchase | $0.39 | +30,000 | 60,000 | +100% | +$11,638 | ||||||
2022-05-24 | LQDA | Liquidia Corp | Lippe Robert A | Chief Operations Officer | P - Purchase | $3.38 | +29,628 | 90,692 | +49% | +$99,997 | ||||||
2022-05-24 | LQDA | Liquidia Corp | Jeffs Roger | CEO | P - Purchase | $3.53 | +28,000 | 1,703,276 | +2% | +$98,812 | ||||||
2022-05-24 | ALT | Altimmune, Inc. | Drutz David | Dir | P - Purchase | $4.50 | +1,200 | 19,345 | +7% | +$5,400 | ||||||
| M | 2022-05-23 | LIAN | Lianbio | Perceptive Advisors LLC | Dir, 10% | P - Purchase | $2.58 | +171,251 | 56,491,211 | 0% | +$442,364 | |||||
2022-05-23 | RLYB | Rallybio Corp | Parmar Kush | Dir, 10% | S - Sale | $13.00 | -100,000 | 3,880,724 | -3% | -$1,300,000 | ||||||
2022-05-23 | RLYB | Rallybio Corp | 5Am Opportunities I, L.P. | 10% | S - Sale | $13.00 | -100,000 | 3,880,724 | -3% | -$1,300,000 | ||||||
| DM | 2022-05-23 | ORGO | Organogenesis Holdings Inc. | Gillheeney Gary S. | Pres, CEO | S - Sale+OE | $5.68 | -197,336 | 398,242 | -33% | -$1,120,557 | |||||
| M | 2022-05-20 | ANGN | Angion Biomedica Corp. | Venkatesan Jay | See Remarks | P - Purchase | $1.23 | +82,200 | 1,721,457 | +5% | +$101,428 | |||||
2022-05-25 | HILS | Hillstream Biopharma Inc. | Milby Randy | CEO | P - Purchase | $0.79 | +1,000 | 2,937,539 | 0% | +$786 | ||||||
2022-05-23 | FOLD | Amicus Therapeutics, Inc. | Crowley John F | COB, CEO | S - Sale | $8.00 | -21,814 | 1,009,048 | -2% | -$174,567 | ||||||
| M | 2022-05-23 | KALA | Kala Pharmaceuticals, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $0.53 | -2,829,314 | 8,045,299 | -26% | -$1,488,844 | |||||
2022-05-23 | RPRX | Royalty Pharma Plc | Lloyd George W. | EVP, Investments, GC | S - Sale | $40.27 | -100,000 | 1,546,831 | -6% | -$4,026,770 | ||||||
| D | 2022-05-23 | ABBV | Abbvie Inc. | Severino Michael | Vice COB | S - Sale+OE | $150.90 | -79,801 | 152,103 | -34% | -$12,041,780 | |||||
2022-05-25 | ONCR | Oncorus, Inc. | Wanstall Rick | CFO, Treasurer | P - Purchase | $1.20 | +3,777 | 51,000 | +8% | +$4,532 | ||||||
| DM | 2022-05-23 | UTHR | United Therapeutics Corp | Rothblatt Martine A | Chairperson, CEO | S - Sale+OE | $213.07 | -6,000 | 651,845 | -1% | -$1,278,438 | |||||
| M | 2022-05-23 | RAPT | Rapt Therapeutics, Inc. | Column Group Ii, LP | 10% | P - Purchase | $12.19 | +26,550 | 3,189,115 | +1% | +$323,745 | |||||
| M | 2022-05-23 | RAPT | Rapt Therapeutics, Inc. | Column Group Ii, LP | 10% | P - Purchase | $12.19 | +26,550 | 3,189,115 | +1% | +$323,745 | |||||
2022-05-24 | EBS | Emergent Biosolutions Inc. | Zoon Kathryn C | Dir | S - Sale | $35.53 | -1,996 | 12,381 | -14% | -$70,918 | ||||||
2022-05-24 | SYBX | Synlogic, Inc. | Jensen Michael Vangsted | CFO | P - Purchase | $1.12 | +9,500 | 39,500 | +32% | +$10,640 | ||||||
2022-05-23 | IRWD | Ironwood Pharmaceuticals Inc | McCourt Thomas A | CEO | S - Sale | $11.50 | -36,308 | 798,881 | -4% | -$417,542 | ||||||
| M | 2022-05-23 | OGEN | Oragenics Inc | Telling Fred | Dir | P - Purchase | $0.29 | +82,173 | 999,916 | +9% | +$23,780 | |||||
2022-05-23 | IRWD | Ironwood Pharmaceuticals Inc | Silver Ronald | Principal Accounting Officer | S - Sale | $11.50 | -120 | 105,073 | 0% | -$1,380 | ||||||
2022-05-23 | IRWD | Ironwood Pharmaceuticals Inc | Shetzline Michael | CMO,SVP,Head-Res, Drug | S - Sale | $11.50 | -10,583 | 266,245 | -4% | -$121,705 | ||||||
2022-05-23 | IRWD | Ironwood Pharmaceuticals Inc | Rickard Jason | SVP, COO | S - Sale | $11.50 | -13,537 | 404,074 | -3% | -$155,676 | ||||||
| D | 2022-05-24 | CMMB | Chemomab Therapeutics Ltd. | Maryles Joel Michael | Dir | P - Purchase | $2.88 | +433 | 1,433 | +43% | +$1,247 | |||||
2022-05-24 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | CEO, 10% | P - Purchase | $1.80 | +2,000 | 3,295,095 | 0% | +$3,600 | ||||||
2022-05-24 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $305.98 | -100,000 | 105,253,810 | 0% | -$30,597,961 | ||||||
| M | 2022-05-23 | CUE | Cue Biopharma, Inc. | Fletcher Aaron G.L. | Dir | P - Purchase | $3.47 | +205,000 | 1,113,867 | +23% | +$711,700 | |||||
2022-05-20 | KMPH | Kempharm, Inc | Seymour Tamara A | Dir | P - Purchase | $4.87 | +200 | 200 | New | +$974 | ||||||
2022-05-23 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | SVP, Comm, Medical Affairs | S - Sale | $8.93 | -1,081 | 329,990 | 0% | -$9,653 | ||||||
2022-05-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO | S - Sale | $3.70 | -139,791 | 1,264,657 | -10% | -$517,227 | ||||||
2022-05-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale | $3.70 | -136,421 | 1,132,992 | -11% | -$504,758 | ||||||
2022-05-20 | ROIV | Roivant Sciences Ltd. | Kumar Rakhi | Chief Accounting Officer | S - Sale | $3.70 | -12,127 | 147,656 | -8% | -$44,870 | ||||||
| M | 2022-05-20 | TRDA | Entrada Therapeutics, Inc. | Baker Bros. Advisors LP | 10% | P - Purchase | $5.82 | +48,509 | 4,465,029 | +1% | +$282,447 | |||||
2022-05-24 | NIHK | Video River Networks, Inc. | Cannabinoid Biosciences, Inc. | Pres, CEO, 10% | P - Purchase | $0.03 | +1,742,044 | 49,756,890 | +4% | +$55,745 | ||||||
| M | 2022-05-20 | LGVN | Longeveron Inc. | Soffer Rock | Dir | S - Sale | $7.83 | -19,500 | 672,351 | -3% | -$152,635 | |||||
2022-05-23 | PHAS | Phasebio Pharmaceuticals Inc | Burkhardt Glen | SVP of HR | S - Sale | $0.79 | -11,248 | 0 | -100% | -$8,886 | ||||||
2022-05-20 | IGMS | Igm Biosciences, Inc. | Topsoe Jakob Haldor | Dir, 10% | P - Purchase | $16.00 | +1,481 | 10,474,026 | 0% | +$23,696 | ||||||
2022-05-20 | ELAN | Elanco Animal Health Inc | Hoover R David | Dir | P - Purchase | $23.33 | +10,000 | 180,187 | +6% | +$233,269 | ||||||
| D | 2022-05-20 | CPRX | Catalyst Pharmaceuticals, Inc. | Tierney David S | Dir | S - Sale+OE | $0.00 | -20,000 | 308,207 | -6% | -$0 | |||||
2022-05-20 | ONCR | Oncorus, Inc. | Wanstall Rick | CFO, Treasurer | P - Purchase | $1.20 | +1,610 | 47,223 | +4% | +$1,932 | ||||||
2022-05-23 | NMTR | 9 Meters Biopharma, Inc. | Constantino Michael T. | Dir | P - Purchase | $0.48 | +16,000 | 60,509 | +36% | +$7,608 | ||||||
2022-05-23 | VIRI | Virios Therapeutics, Inc. | Walsh Angela | SVP OF FINANCE | P - Purchase | $4.58 | +2,000 | 3,000 | +200% | +$9,150 | ||||||
2022-05-23 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $302.73 | -118,856 | 105,353,810 | 0% | -$35,981,664 | ||||||
2022-05-23 | VIRI | Virios Therapeutics, Inc. | Duncan Gregory Scott | CEO | P - Purchase | $4.52 | +7,500 | 32,461 | +30% | +$33,900 | ||||||
2022-05-20 | OCUP | Ocuphire Pharma, Inc. | Manuso James S J | Dir | P - Purchase | $1.99 | +5,000 | 21,570 | +30% | +$9,950 | ||||||
| M | 2022-05-19 | ANGN | Angion Biomedica Corp. | Nissenson Allen | Dir | P - Purchase | $1.16 | +9,383 | 9,383 | New | +$10,925 | |||||
| M | 2022-05-20 | AMTI | Applied Molecular Transport Inc. | Lamond David | Dir | P - Purchase | $3.17 | +66,500 | 1,077,519 | +7% | +$210,850 | |||||
| M | 2022-05-19 | MRSN | Mersana Therapeutics, Inc. | Hack Andrew A. F. | Dir | P - Purchase | $3.46 | +215,599 | 8,302,999 | +3% | +$746,437 | |||||
| M | 2022-05-19 | OCUP | Ocuphire Pharma, Inc. | Sooch Mina | Pres, CEO | P - Purchase | $2.05 | +25,000 | 425,022 | +6% | +$51,179 | |||||
2022-05-19 | RPRX | Royalty Pharma Plc | Reddoch James F. | EVP, Chief Scientific Officer | S - Sale | $40.44 | -75,000 | 1,120,830 | -6% | -$3,033,128 | ||||||
| M | 2022-05-19 | RPRX | Royalty Pharma Plc | Riggs Rory B | Dir | S - Sale | $39.42 | -150,000 | 551,899 | -21% | -$5,913,306 | |||||
| M | 2022-05-19 | GANX | Gain Therapeutics, Inc. | Richman Eric I | CEO | P - Purchase | $2.79 | +13,256 | 230,076 | +6% | +$37,034 | |||||
2022-05-20 | ARDX | Ardelyx, Inc. | Rosenbaum David P. | Chief Development Officer | S - Sale | $0.67 | -2,013 | 533,014 | 0% | -$1,352 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |